Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance

Journal of the American College of Cardiology

Volumn 28, Issue 5, 1996, Pages 1119-1126

  Strauer, Bodo E ^a   Heidland, Ulrich E ^a   Heintzen, Matthias P ^a   Schwartzkopff, Bodo ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE PERFORMANCE; HEMODYNAMICS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRACARDIAC DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARRHYTHMIA; ASPIRIN; CORONARY VESSELS; DIPYRIDAMOLE; FEMALE; HEART; HEMODYNAMIC PROCESSES; HEPARIN; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PREOPERATIVE CARE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0030297741     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00307-5     Document Type: Article

References (31)

1. 1. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res 1993;27:542-50.
2. 2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
3. 3. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation 1990;82:609-19.
4. 4. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct-size-limiting effect of ischemic preconditioning. Circulation 1992;86:979-85.
5. 5. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995;91:37-47.
6. 6. Van der Heide RS, Reimer KA, Jennings RB. Adenosine stows ischemic metabolism in canine myocardium in vitro: relationship to ischemic preconditioning. Cardiovasc Res 1993;27:669-73.
7. 7. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-42.
8. 8. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990;15:775-83.
9. 9. Fitzgerald GA. Drug therapy: dipyridamole. New Engl J Med 1987;316: 1247-57.
10. 10. Kübler W. Die Bindung des Koronardilatators Dipyridamol an die Plasmaeiweißkörper des Menschen. Arch Kreislaufforsch 1971;64:115-26.
11. 11. Kübler W, Spieckermann PG, Bretschneider HJ. Influence of dipyridamole (Persantin) on myocardial adenosine metabolism. J Mol Cell Cardiol 1970;1:23-37.
12. 12. Strauer BE, Heidland UE, Vogt M, Schwartzkopff B, Heintzen MP. Protektion und "Preconditioning" des menschlichen Herzens während perkutaner transluminaler coronarangioplastie (PTCA) durch intrakoronare Dipyridamol-Applikation. Med Klin 1995;90:125-30.
13. 13. Prachar H. Veränderungen während PTCA: ein Modell der Ischämie am Menschen. Acta Med Austriaca 1991;18 Suppl 42:1-35.
14. 14. Heintzen MP, Motz W, Leschke M, et al. PTCA im Stadium des akuten Myokardinfarktes: Hospitalverlauf von 785 konsekutiven Patienten. Z Kardiol 1994;83:404-13.
15. 15. Strauer BE. The Heart in Hypertension. 3rd ed. Berlin: Springer-Verlag, 1991:S34.
16. 16. Böhm M, Meyer W. Mügge A, Schmilz W, Scholz H. Functional evidence for the existence of adenosine receptors in the human heart. Eur J Pharmacol 1985;116:323-6.
17. 17. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 70:761-845.
18. 18. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic preconditioning protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
19. 19. Schömig A, Fischer S, Kurz T, Richardt G, Schömig E. Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ Res 1987;60:194-205.
20. 20. Richardt G, Waas W, Kranzhofer R, Mayer E, Schömig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 1987;61:117-23.
21. 21. Lombardi F, Verrier LR, Lown B. Relationship between sympathetic neural activity, coronary dynamics and vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Am Heart J 1983;105:958-65.
22. 22. Neely JR, Grotyohann LW. Role of glycolytic products in damage to ischemic myocardium: dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 1984;55:816-24.
23. 23. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaption to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic and metabolic features. Circulation 1990;82:2044-51.
24. 24. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983;158:1160-77.
25. 25. Parratt J, Vegh A. Pronounced antiarrhythmic effects of ischemic preconditioning. Cardioscience 1994;5:9-18.
26. 26. Van Wylen DG. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation 1994;89:2283-9.
27. 27. Cox DA, Vita JA, Treasure CB, Fish RD, Selwyn AP, Ganz P. Reflex increase in blood pressure during the intracoronary administration of adenosine in man. J Clin Invest 1989;84:592-6.
28. 28. Gregg DE. Effect of coronary perfusion pressure or coronary flow on oxygen usage of the myocardium. Circ Res 1963;13:497-500.
29. 29. May-Newman K, Omens JH, Pavelec RS, McCulloch AD. Three dimensional transmural mechanical interaction between the coronary vasculature and passive myocardium in the dog. Circ Res 1994;74:1166-78.
30. 30. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982;66:1146-9.
31. 31. De Boer LWV, Ingwall JS, Kloner RA, Braunwald E. Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci USA 1980;77:5471-5.